Primary Immunodeficiency Therapeutic Market, Global Outlook and Forecast 2022-2028

June 2022 | 63 pages | ID: P565E13D53A2EN
Market Monitor Global

Abstracts

Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.

This report contains market size and forecasts of Primary Immunodeficiency Therapeutic in Global, including the following market information:

Global Primary Immunodeficiency Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Primary Immunodeficiency Therapeutic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immunoglobulin Replacement Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Primary Immunodeficiency Therapeutic include Baxter International, Takeda Pharmaceutical, CSL Limited, Octapharma, Kedrion Biopharma, Bio Products Laboratory, LFB group, Grifols and Lupin Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Immunodeficiency Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Immunodeficiency Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Type, 2021 (%)

• Immunoglobulin Replacement Therapy
• Stem Cell or Bone Marrow Transplantation
• Antibiotic Therapy
• Gene Therapy
• Others

Global Primary Immunodeficiency Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Primary Immunodeficiency Therapeutic Market Segment Percentages, by Application, 2021 (%)

• Antibody Deficiency
• Cellular Immunodeficiency
• Innate Immune Disorders
• Others

Global Primary Immunodeficiency Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Primary Immunodeficiency Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Primary Immunodeficiency Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Primary Immunodeficiency Therapeutic revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Baxter International
• Takeda Pharmaceutical
• CSL Limited
• Octapharma
• Kedrion Biopharma
• Bio Products Laboratory
• LFB group
• Grifols
• Lupin Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Primary Immunodeficiency Therapeutic Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PRIMARY IMMUNODEFICIENCY THERAPEUTIC OVERALL MARKET SIZE

2.1 Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028
2.2 Global Primary Immunodeficiency Therapeutic Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Primary Immunodeficiency Therapeutic Players in Global Market
3.2 Top Global Primary Immunodeficiency Therapeutic Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Primary Immunodeficiency Therapeutic Companies in Global Market, by Revenue in 2021
3.5 Global Companies Primary Immunodeficiency Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Players in Global Market
  3.6.1 List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies
  3.6.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Primary Immunodeficiency Therapeutic Market Size Markets, 2021 & 2028
  4.1.2 Immunoglobulin Replacement Therapy
  4.1.3 Stem Cell or Bone Marrow Transplantation
  4.1.4 Antibiotic Therapy
  4.1.5 Gene Therapy
  4.1.6 Others
4.2 By Type - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
  4.2.1 By Type - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
  4.2.2 By Type - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
  4.2.3 By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Primary Immunodeficiency Therapeutic Market Size, 2021 & 2028
  5.1.2 Antibody Deficiency
  5.1.3 Cellular Immunodeficiency
  5.1.4 Innate Immune Disorders
  5.1.5 Others
5.2 By Application - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
  5.2.1 By Application - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
  5.2.2 By Application - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
  5.2.3 By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Primary Immunodeficiency Therapeutic Market Size, 2021 & 2028
6.2 By Region - Global Primary Immunodeficiency Therapeutic Revenue & Forecasts
  6.2.1 By Region - Global Primary Immunodeficiency Therapeutic Revenue, 2017-2022
  6.2.2 By Region - Global Primary Immunodeficiency Therapeutic Revenue, 2023-2028
  6.2.3 By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  6.3.2 US Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.3.3 Canada Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.3.4 Mexico Primary Immunodeficiency Therapeutic Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  6.4.2 Germany Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.3 France Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.4 U.K. Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.5 Italy Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.6 Russia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.7 Nordic Countries Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.4.8 Benelux Primary Immunodeficiency Therapeutic Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  6.5.2 China Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.5.3 Japan Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.5.4 South Korea Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.5.5 Southeast Asia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.5.6 India Primary Immunodeficiency Therapeutic Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  6.6.2 Brazil Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.6.3 Argentina Primary Immunodeficiency Therapeutic Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, 2017-2028
  6.7.2 Turkey Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.7.3 Israel Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.7.4 Saudi Arabia Primary Immunodeficiency Therapeutic Market Size, 2017-2028
  6.7.5 UAE Primary Immunodeficiency Therapeutic Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Baxter International
  7.1.1 Baxter International Corporate Summary
  7.1.2 Baxter International Business Overview
  7.1.3 Baxter International Primary Immunodeficiency Therapeutic Major Product Offerings
  7.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.1.5 Baxter International Key News
7.2 Takeda Pharmaceutical
  7.2.1 Takeda Pharmaceutical Corporate Summary
  7.2.2 Takeda Pharmaceutical Business Overview
  7.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Major Product Offerings
  7.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.2.5 Takeda Pharmaceutical Key News
7.3 CSL Limited
  7.3.1 CSL Limited Corporate Summary
  7.3.2 CSL Limited Business Overview
  7.3.3 CSL Limited Primary Immunodeficiency Therapeutic Major Product Offerings
  7.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.3.5 CSL Limited Key News
7.4 Octapharma
  7.4.1 Octapharma Corporate Summary
  7.4.2 Octapharma Business Overview
  7.4.3 Octapharma Primary Immunodeficiency Therapeutic Major Product Offerings
  7.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.4.5 Octapharma Key News
7.5 Kedrion Biopharma
  7.5.1 Kedrion Biopharma Corporate Summary
  7.5.2 Kedrion Biopharma Business Overview
  7.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Major Product Offerings
  7.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.5.5 Kedrion Biopharma Key News
7.6 Bio Products Laboratory
  7.6.1 Bio Products Laboratory Corporate Summary
  7.6.2 Bio Products Laboratory Business Overview
  7.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Major Product Offerings
  7.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.6.5 Bio Products Laboratory Key News
7.7 LFB group
  7.7.1 LFB group Corporate Summary
  7.7.2 LFB group Business Overview
  7.7.3 LFB group Primary Immunodeficiency Therapeutic Major Product Offerings
  7.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.7.5 LFB group Key News
7.8 Grifols
  7.8.1 Grifols Corporate Summary
  7.8.2 Grifols Business Overview
  7.8.3 Grifols Primary Immunodeficiency Therapeutic Major Product Offerings
  7.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.8.5 Grifols Key News
7.9 Lupin Pharmaceuticals
  7.9.1 Lupin Pharmaceuticals Corporate Summary
  7.9.2 Lupin Pharmaceuticals Business Overview
  7.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Major Product Offerings
  7.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue in Global Market (2017-2022)
  7.9.5 Lupin Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Primary Immunodeficiency Therapeutic Market Opportunities & Trends in Global Market
Table 2. Primary Immunodeficiency Therapeutic Market Drivers in Global Market
Table 3. Primary Immunodeficiency Therapeutic Market Restraints in Global Market
Table 4. Key Players of Primary Immunodeficiency Therapeutic in Global Market
Table 5. Top Primary Immunodeficiency Therapeutic Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Primary Immunodeficiency Therapeutic Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Primary Immunodeficiency Therapeutic Revenue Share by Companies, 2017-2022
Table 8. Global Companies Primary Immunodeficiency Therapeutic Product Type
Table 9. List of Global Tier 1 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Immunodeficiency Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Primary Immunodeficiency Therapeutic Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Primary Immunodeficiency Therapeutic Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2023-2028
Table 30. Baxter International Corporate Summary
Table 31. Baxter International Primary Immunodeficiency Therapeutic Product Offerings
Table 32. Baxter International Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 33. Takeda Pharmaceutical Corporate Summary
Table 34. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product Offerings
Table 35. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 36. CSL Limited Corporate Summary
Table 37. CSL Limited Primary Immunodeficiency Therapeutic Product Offerings
Table 38. CSL Limited Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 39. Octapharma Corporate Summary
Table 40. Octapharma Primary Immunodeficiency Therapeutic Product Offerings
Table 41. Octapharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 42. Kedrion Biopharma Corporate Summary
Table 43. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product Offerings
Table 44. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 45. Bio Products Laboratory Corporate Summary
Table 46. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product Offerings
Table 47. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 48. LFB group Corporate Summary
Table 49. LFB group Primary Immunodeficiency Therapeutic Product Offerings
Table 50. LFB group Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 51. Grifols Corporate Summary
Table 52. Grifols Primary Immunodeficiency Therapeutic Product Offerings
Table 53. Grifols Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)
Table 54. Lupin Pharmaceuticals Corporate Summary
Table 55. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product Offerings
Table 56. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Primary Immunodeficiency Therapeutic Segment by Type in 2021
Figure 2. Primary Immunodeficiency Therapeutic Segment by Application in 2021
Figure 3. Global Primary Immunodeficiency Therapeutic Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Primary Immunodeficiency Therapeutic Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Primary Immunodeficiency Therapeutic Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2021
Figure 8. By Type - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 9. By Application - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 10. By Region - Global Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 11. By Country - North America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 12. US Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 16. Germany Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 17. France Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 24. China Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 28. India Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 30. Brazil Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Primary Immunodeficiency Therapeutic Revenue Market Share, 2017-2028
Figure 33. Turkey Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Primary Immunodeficiency Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 37. Baxter International Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. CSL Limited Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Octapharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. LFB group Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Grifols Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)